Pooled analyses of three short-term randomised controlled trials found that esketamine nasal spray plus a newly initiated oral antidepressant produced greater reductions in MADRS total score than antidepressant plus placebo in both women and men with treatment‑resistant depression, with no significant sex effect or treatment-by-sex interaction. Overall safety was similar between sexes, although nausea, dissociation, dizziness and vertigo were reported more frequently in women.
- Published
- Journal
- Archives of Women's Mental Health
- Authors
- Jones, R. R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E. J., Canuso, C. M., Nicholson, S.